Physician profile
Michael Auerbach
NPI 1336199942
$64,396.91
in general payments reported to CMS, 2019-2025
76 companies · $1,167 in 2025
The $1,167 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,737 · 2020: $27K · 2021: $8,622 · 2022: $11K · 2023: $11K · 2024: $2,051 · 2025: $1,167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,000 · Food and Beverage: $5,491 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,000.00 |
| Food and Beverage | $5,490.71 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $39,355.33 | 2020-2023 | Monoferric |
| Whitehall International INC | $4,000.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $3,214.05 | 2019-2025 | Calquence |
| Pfizer INC. | $2,405.24 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,737.93 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,136.22 | 2019-2025 | Opdivo, Krazati, Opdualag |
| Amag Pharmaceuticals, INC. | $1,026.98 | 2019 | |
| Amgen INC. | $828.15 | 2019-2023 | Lumakras, Evenity, Prolia |
| Janssen Biotech, INC. | $724.86 | 2019-2025 | Tecvayli, Erleada, Talvey |
| Genentech USA, INC. | $698.19 | 2019-2024 | Polivy, Lunsumio, Gazyva |
| Alexion Pharmaceuticals, INC. | $645.05 | 2019-2025 | Ultomiris |
| Abbvie INC. | $579.25 | 2019-2025 | Venclexta |
| Celgene Corporation | $560.86 | 2019-2025 | Reblozyl, Pomalyst |
| Exelixis INC. | $529.73 | 2019-2025 | Cabometyx |
| Glaxosmithkline, LLC. | $462.23 | 2020-2025 | Jemperli, Zejula, Ojjaara |
Show all 75 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Auerbach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.